Novacyt S.A. (NVYTF)
Novacyt S.A. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Le Vésinet, IF, FR. The stock last traded at $0.48, down 0.00% on the session, giving a market capitalisation of $34.8M. On trailing twelve-month figures it carries a trailing P/E of -1.03, a net margin of -123.9%. Its beta of 1.11 implies it has historically moved more than the broad market.
Novacyt S.A., along with its subsidiaries, specializes in the global development, manufacturing, bespoke design, and commercialization of diagnostic products. These offerings are instrumental in identifying cancer and infectious diseases, reaching markets across the United Kingdom, Europe, the United States, Asia Pacific, the Middle East, and Africa. The company's activities are organized into three primary divisions: Primer Design, Lab21 Products, and IT-IS International. Primer Design is responsible for conceiving, producing, and distributing molecular real-time qPCR testing equipment and reagents specifically for infectious disease diagnosis. Lab21 Products focuses on crafting and delivering a spectrum of protein-based in-vitro diagnostic (IVD) solutions for infectious ailments. Lastly, IT-IS International develops and manufactures PCR devices catering to both the life sciences and food testing industries. Novacyt's customer base includes hospitals and various corporate entities. Founded in 2006, the firm is headquartered in Vélizy-Villacoublay, France.
Novacyt S.A. is most often compared with the following Healthcare names: